Grant: Discovery Grants Program - Individual
Simon Fraser University
$58,000.00
The Design of Novel Chelating Ligands for Unconventional Radiometals
EF 2024-25
Résumé
Metallic radioisotopes (aka radiometals) possess vast chemical diversity and range of radioactive emission properties (e.g.; decay emissions, half-lives), making them extremely amenable for incorporation into radiopharmaceuticals for molecular imaging or targeted radionuclide therapy. Despite this potential utility, the use of radiometals is hindered by isotope availability issues, and identification of appropriate chelating ligands. Chelating ligands in radiopharmaceutical design are molecules that bind tightly to radiometals. The ligand holds the metal in a specific environment but does not deliver the radiometal to a specific target. Thus, covalent attachment to a targeting vector (e.g.; peptide, antibody) is required. To manipulate a radiometal in radiopharmaceutical design, a concrete understanding of the metal's coordination chemistry is required. Many radiometals with favourable radioactive emissions are underdeveloped and lack this fundamental understanding; my research program aims to address this gap in knowledge. The short-term objectives of this inorganic radiochemistry research program are to design, synthesize, characterize, and study novel chelating ligands that possess superior stability and specificity compared to commercial standards, for cutting-edge radiometals such as actinium-225, mercury-197m, and antimony-119. We will also investigate methods to attach these novel ligands to biomolecules (e.g.; peptides, DNA intercalators, antibodies) and study how these systems can be efficiently delivered to in vitro molecular targets. My joint appointment with TRIUMF - Canada's particle accelerator centre, will give my team complete access to these underdeveloped but promising radiometals. TRIUMF is one of only a few world institutions where this research is possible, placing us at the forefront of this field. This research intersects the fields of organic/inorganic chemistry, molecular biology, and radiochemistry.
Novelty & Significance: The work proposed here is fundamental to elucidate coordination chemistry of underdeveloped radiometals, by investigating new chelating ligands. The novel ligand architectures that will be studied will help the inorganic chemistry research community to intimately understand and exploit the effects of metal-chelate complex choice in radiopharmaceutical design. A long-term outcome of this research will be to improve imaging and treatment options in nuclear medicine applications to the benefit of many Canadians.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2019-07207
Name nom
Ramogida, Caterina
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2019
Award amount
58000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3603
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Bio-inorganic chemistry
Research subject fr
Chimie bio-inorganique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
The Design of Novel Chelating Ligands for Unconventional Radiometals
Keywords
radiochemistry; chelating ligands; coordination chemistry; metallic radionuclides; targeted radionuclide therapy; alpha particles; ligand design; radiopharmaceuticals; nuclear medicine; positron emission tomography
Application summary
Metallic radioisotopes (aka radiometals) possess vast chemical diversity and range of radioactive emission properties (e.g.; decay emissions, half-lives), making them extremely amenable for incorporation into radiopharmaceuticals for molecular imaging or targeted radionuclide therapy. Despite this potential utility, the use of radiometals is hindered by isotope availability issues, and identification of appropriate chelating ligands. Chelating ligands in radiopharmaceutical design are molecules that bind tightly to radiometals. The ligand holds the metal in a specific environment but does not deliver the radiometal to a specific target. Thus, covalent attachment to a targeting vector (e.g.; peptide, antibody) is required. To manipulate a radiometal in radiopharmaceutical design, a concrete understanding of the metal's coordination chemistry is required. Many radiometals with favourable radioactive emissions are underdeveloped and lack this fundamental understanding; my research program aims to address this gap in knowledge. The short-term objectives of this inorganic radiochemistry research program are to design, synthesize, characterize, and study novel chelating ligands that possess superior stability and specificity compared to commercial standards, for cutting-edge radiometals such as actinium-225, mercury-197m, and antimony-119. We will also investigate methods to attach these novel ligands to biomolecules (e.g.; peptides, DNA intercalators, antibodies) and study how these systems can be efficiently delivered to in vitro molecular targets. My joint appointment with TRIUMF - Canada's particle accelerator centre, will give my team complete access to these underdeveloped but promising radiometals. TRIUMF is one of only a few world institutions where this research is possible, placing us at the forefront of this field. This research intersects the fields of organic/inorganic chemistry, molecular biology, and radiochemistry.
Novelty & Significance: The work proposed here is fundamental to elucidate coordination chemistry of underdeveloped radiometals, by investigating new chelating ligands. The novel ligand architectures that will be studied will help the inorganic chemistry research community to intimately understand and exploit the effects of metal-chelate complex choice in radiopharmaceutical design. A long-term outcome of this research will be to improve imaging and treatment options in nuclear medicine applications to the benefit of many Canadians.